Tag: Drug Approvals
FDA Approves Vabomere for Complicated UTIs
IV antibiotic sanctioned for certain complicated urinary tract infections, including pyelonephritis
FDA Approves New Treatment for Acute Lymphoblastic Leukemia
For patients with relapsed or refractory B-cell ALL who have received one or two prior treatments
Studies Used for FDA Approval of Device Changes Often Low Quality
And, efficacy of drugs granted accelerated approval often confirmed only years after approval
FDA Approves Mavyret for Hepatitis C
Combo drug is first approved therapy for hepatitis C to require as few as eight weeks of treatment
FDA Approves New Treatment for Acute Myeloid Leukemia
Vyxeos combines two previously approved drugs -- daunorubicin and cytarabine
FDA Approves Idhifa for Some With Acute Myeloid Leukemia
For adults with relapsed or refractory AML who have an IDH2 genetic mutation
FDA Approves Imbruvica to Treat Chronic Graft Versus Host Disease
Drug sanctioned for patients with cGVHD who do not respond to other forms of therapy
FDA Approves First Neonatal MRI Device
Device designed for neonatal brain and head imaging in intensive care units
FDA Approves Nerlynx to Help Prevent HER2+ Breast CA Return
Drug is a kinase inhibitor that works by blocking several enzymes that promote cell growth
FDA Approves Endari for the Treatment of Sickle Cell Disease
First treatment approved for patients with sickle cell disease in almost 20 years
